In The News

Lawyering Through COVID-19: What We’ve Heard From the Practices

Bloomberg Law

28 May 2020

Bethany Hills spoke to Bloomberg Law about how her practice in the healthcare and pharmaceutical industries has changed during the coronavirus pandemic.

According to Bethany, the FDA has been uncharacteristically quick to respond to requests for Emergency Use Authorization for diagnostics and other COVID-related products. “When we have general questions they get answered within 24 hours,” Bethany said. “In the non-COVID world, that is not our experience. It can be a really long time to get on the FDA’s calendar – sometimes meetings take weeks to months to get scheduled. This has been a breath of fresh air to interacting with the FDA.”

Bethany said that there are also challenges here as well, and that she and others are scrambling to keep up with a steady stream of FDA policy changes for companies developing virus-related diagnostics, treatments, and vaccines. Lawyers have “frustrations with how this is rolling out,” according to Bethany. “There are just so many FDA policies and there’s so much activity, we have a whole team of people trying to stay up to date. It literally changes on a day-to-day basis.”

Read the full article (subscription required).



Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.